The FDA approved Boruzu, a new presentation of bortezomib, for subcutaneous or intravenous administration in patients with multiple myeloma and mantle cell lymphoma.
Donna Catamero, ANP-BC, OCN, CCRC, discusses the importance of quickly identifying and managing adverse effects from CAR T-cell therapy in patients with multiple myeloma.
Ciltacabtagene autoleucel demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory multiple myeloma refractory to lenalidomide.